Dynavax Technologies (NASDAQ:DVAX) is up 17% premarket after collaborating
with the University of Queensland as part of a Coalition for Epidemic
Preparedness initiative to develop a vaccine to prevent COVID-19.
The company is providing technical expertise and toll-like receptor 9 agonist adjuvant, CpG 1018, to support this initiative.
CpG 1018 is used in HEPLISAV-B [Hepatitis B
Vaccine (Recombinant), Adjuvanted]. It provides a well‑developed
technology and a significant safety database, accelerating the
development of a COVID-19 vaccine.
https://seekingalpha.com/news/3547415-dynavaxplus-17-premarket-on-covidminus-19-vaccine-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.